Clinical Trial Update: Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating interferon alfa-2b with or without bevacizumab in advanced renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Kidney Cancer | Phase 3 | Status: COMPLETED